No Data
No Data
Chimerix To Submit Dordaviprone For Accelerated Approval To U.S. FDA For Patients With Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Chimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug Dordaviprone
Trending Stocks Today | Chimerix Soars 162.42% Post-Market
Express News | Chimerix Inc - Potential Approval for Dordaviprone in Q3 2025
Express News | Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
No Data